Compare
ANI Pharmaceuticals vs Lilly (Eli) (ANIP vs LLY)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year ANI Pharmaceuticals (ANIP) returned -27.2% and Lilly (Eli) (LLY) +46.2%; so far this year the figures are -14.6% and +26.0%.
Lilly (Eli) is the larger company by market value, about 872.4 times the size of ANI Pharmaceuticals.
On trailing earnings, ANIP trades at 13.5 times and LLY at 43.9 times.
Revenue grew +25.9% at ANIP and +45.5% at LLY over the last year.
ANIP pays no dividend. LLY yields 0.49%.
Data as of the latest close. Not investment advice.
Relative performance
| ANIP | LLY | |
|---|---|---|
| Price | $67.41 | $1,354.00 |
| 1-day | -3.17% | -0.79% |
| YTD | -14.61% | +25.99% |
| 1 year | -27.22% | +46.25% |
| 3 years | +9.33% | +144.20% |
| Market cap | $1.5B | $1.27T |
| P/E | 13.5 | 43.9 |
| P/S | 1.40 | 14.73 |
| P/B | 2.29 | 31.63 |
| Revenue growth | +25.90% | +45.50% |
| EPS growth | +207.40% | +50.70% |
| Gross margin % | 61.1 | 83.6 |
| Net margin % | 11.2 | 31.9 |
| ROE % | 18.3 | 68.5 |
| Debt / equity | 0.47 | 1.23 |
| FCF yield % | 14.1 | 2.4 |
| Dividend yield % | — | 0.49 |
| Beta | 0.29 | 0.29 |
| RSI (14) | 34.9 | 61.1 |
| Technical rating |